- Home
- BANF vs RARE Comparison
BANF vs RARE Comparison
Compare BANF & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANF | RARE |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.2B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BANF | RARE |
|---|---|---|
| Price | $113.60 | $36.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $128.00 | $85.20 |
| AVG Volume (30 Days) | 125.3K | ★ 1.4M |
| Earning Date | 01-22-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | ★ 13.17 | N/A |
| EPS | ★ 7.04 | N/A |
| Revenue | ★ $666,553,000.00 | $630,598,000.00 |
| Revenue This Year | $11.96 | $19.09 |
| Revenue Next Year | $3.80 | $20.62 |
| P/E Ratio | $16.11 | ★ N/A |
| Revenue Growth | 9.57 | ★ 20.63 |
| 52 Week Low | $97.02 | $25.81 |
| 52 Week High | $138.77 | $49.19 |
Technical Indicators
Market Signals| Indicator | BANF | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 61.44 |
| Support Level | $108.54 | $35.65 |
| Resistance Level | $113.06 | $36.74 |
| Average True Range (ATR) | 3.08 | 1.43 |
| MACD | 0.61 | 0.18 |
| Stochastic Oscillator | 78.90 | 53.64 |
Price Performance
Historical ComparisonAbout BANF BancFirst Corporation
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.